Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bing Z Carter

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
Nature Communications|September 19, 2023
ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemiaJessica Ebner, Johannes Schmoellerl, Martin Piontek, et al.
Blood|May 31, 2012
Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AMLBing Z Carter, Yihua Qiu, Xuelin Huang, et al.
Blood|November 2, 2006
MEK blockade converts AML differentiating response to retinoids into extensive apoptosisMichele Milella, Marina Konopleva, Cristina M Precupanu, et al.
Oncotarget|September 7, 2014
Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanismsXin Chen, Xianping Shi, Chong Zhao, et al.
Cell Death & Disease|August 29, 2023
Bcl-2 inhibition combined with PPARα activation synergistically targets leukemic stem cell-like cells in acute myeloid leukemiaChendi Xie, Hui Zhou, Dongmei Qin, et al.
Journal of the National Cancer Institute|February 15, 2014
Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agentsBing Z Carter, Po Yee Mak, Duncan H Mak, et al.
Blood Cancer Journal|April 23, 2023
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimeticsBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Blood Cancer Journal|May 16, 2023
Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimeticsBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Molecular Cancer Therapeutics|April 1, 2022
Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem CellsBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Blood|July 3, 2025
Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemiaBing Z Carter, Po Yee Mak, Edward Ayoub, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Nature Communications|September 19, 2023
ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemiaJessica Ebner, Johannes Schmoellerl, Martin Piontek, et al.
Blood|May 31, 2012
Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AMLBing Z Carter, Yihua Qiu, Xuelin Huang, et al.
Blood|November 2, 2006
MEK blockade converts AML differentiating response to retinoids into extensive apoptosisMichele Milella, Marina Konopleva, Cristina M Precupanu, et al.
Oncotarget|September 7, 2014
Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanismsXin Chen, Xianping Shi, Chong Zhao, et al.
Cell Death & Disease|August 29, 2023
Bcl-2 inhibition combined with PPARα activation synergistically targets leukemic stem cell-like cells in acute myeloid leukemiaChendi Xie, Hui Zhou, Dongmei Qin, et al.
Journal of the National Cancer Institute|February 15, 2014
Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agentsBing Z Carter, Po Yee Mak, Duncan H Mak, et al.
Blood Cancer Journal|April 23, 2023
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimeticsBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Blood Cancer Journal|May 16, 2023
Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimeticsBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Molecular Cancer Therapeutics|April 1, 2022
Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem CellsBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Blood|July 3, 2025
Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemiaBing Z Carter, Po Yee Mak, Edward Ayoub, et al.
Pageof 8